Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
Reads0
Chats0
TLDR
Nontreatment and undertreatment of patients with psoriasis and psoriatic arthritis remain a significant problem in the United States and efforts in advocacy and education are necessary to ensure that effective treatments are accessible to this patient population.Abstract:
Importance Psoriasis and psoriatic arthritis inflict significant morbidity. Data on undertreatment, treatment use, and treatment satisfaction are paramount to identify priority areas for advocacy, education, and research to improve patient outcomes. Objectives To determine the extent of nontreatment and undertreatment of psoriatic diseases, trends in treatment use, treatment satisfaction, and reasons for medication discontinuation among patients with psoriasis and psoriatic arthritis. Design, Setting, and Participants We used the national survey data collected by the National Psoriasis Foundation via biannual surveys conducted from January 1, 2003, through December 31, 2011, in the United States. Survey data were collected from randomly sampled patients with psoriasis and psoriatic arthritis in the US population from a database of more than 76 000 patients with psoriatic diseases. Main Outcomes and Measures Nontreatment, undertreatment, and treatment trends determined by the use of prescription medication (topical, phototherapeutic, oral systemic, and biologic), as well as treatment satisfaction and reasons for medication discontinuation. Results A total of 5604 patients with psoriasis or psoriatic arthritis completed the survey. From 2003 through 2011, patients who were untreated ranged from 36.6% to 49.2% of patients with mild psoriasis, 23.6% to 35.5% of patients with moderate psoriasis, and 9.4% to 29.7% of patients with severe psoriasis. Among those receiving treatment, 29.5% of patients with moderate psoriasis and 21.5% of patients with severe psoriasis were treated with topical agents alone. The most frequently used phototherapy modality is UV-B, whereas methotrexate is the most commonly used oral agent. Although adverse effects and a lack of effectiveness were primary reasons for discontinuing biological agents, the inability to obtain adequate insurance coverage was among the top reasons for discontinuation. Overall, 52.3% of patients with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatment. Conclusions and Relevance Nontreatment and undertreatment of patients with psoriasis and psoriatic arthritis remain a significant problem in the United States. While various treatment modalities are available for psoriasis and psoriatic arthritis, widespread treatment dissatisfaction exists. Efforts in advocacy and education are necessary to ensure that effective treatments are accessible to this patient population.read more
Citations
More filters
Journal ArticleDOI
Psoriasis and comorbid diseases: Epidemiology.
Junko Takeshita,Sungat K. Grewal,Sinead Langan,Nehal N. Mehta,Alexis Ogdie,Abby S. Van Voorhees,Joel M. Gelfand +6 more
TL;DR: A rapidly expanding body of literature in various populations and settings supports additional associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders.
Journal ArticleDOI
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim A. Papp,Kristian Reich,Craig L. Leonardi,Leon H Kircik,Sergio Chimenti,Richard G. Langley,Chia Chi Hu,R. Stevens,Robert M. Day,Kenneth B. Gordon,Neil J. Korman,Christopher E.M. Griffiths +11 more
TL;DR: Apremilast was effective in moderate to severe plaque psoriasis and no new significant adverse events emerged with continued ap Remilast exposure versus the placebo-controlled period.
Journal ArticleDOI
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
Mark Lebwohl,Hervé Bachelez,Jonathan Barker,Giampiero Girolomoni,Arthur Kavanaugh,Richard G. Langley,Carle Paul,Lluís Puig,Kristian Reich,Peter C.M. van de Kerkhof +9 more
TL;DR: Several identified unmet needs warrant additional attention and action, including improved severity assessment, PsA screening, patient awareness, and treatment options.
Journal ArticleDOI
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
Laura C. Coates,Anna R. Moverley,Lucy McParland,Sarah Brown,Nuria Navarro-Coy,John O’Dwyer,David M. Meads,Paul Emery,Philip G. Conaghan,Philip S. Helliwell +9 more
TL;DR: Tight control of psoriatic arthritis disease activity through a treat-to-target approach significantly improves joint outcomes for newly diagnosed patients, with no unexpected serious adverse events reported.
Journal ArticleDOI
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†
Kim A. Papp,Kristian Reich,Carle Paul,Andrew Blauvelt,W. Baran,Chantal Bolduc,Darryl Toth,Richard G. Langley,J. Cather,Alice B. Gottlieb,Diamant Thaçi,James G. Krueger,Chris B. Russell,Cassandra E Milmont,Joanne Li,Paul Klekotka,Gregory Kricorian,Ajay Nirula +17 more
TL;DR: The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis and is associated with atypical immune responses and central nervous system disorders.
References
More filters
Journal ArticleDOI
Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis
Francesca Sampogna,Mary-Margaret Chren,C.F. Melchi,Paolo Pasquini,Stefano Tabolli,Damiano Abeni +5 more
TL;DR: This study highlights the need to understand more fully the rationale behind the continued use of these devices, as well as the rationale for continued use, in patients with Psoriasis.
Journal ArticleDOI
Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey
TL;DR: Whether patients with psoriasis with moderate or severe disease are being treated with systemic therapy with a focus on body surface area has not been validated but has been used in several published studies.
Journal ArticleDOI
Psoriasis Epidemiology: The Interplay of Genes and the Environment
TL;DR: A systematic review to explore the global prevalence and incidence of psoriasis and the factors that potentially account for this variability include climate, genetic susceptibility, and environmental antigen exposure.
Journal ArticleDOI
Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy.
TL;DR: Biologic agents offer new hope for patients with psoriasis that their chronic condition can be controlled in a manner that improves their quality of life and may lead to high levels of satisfaction with their treatment.
Related Papers (5)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
Ulrich Mrowietz,Knud Kragballe,Kristian Reich,Ph.I. Spuls,Christopher E.M. Griffiths,Alexander Nast,J. Franke,Christina Antoniou,Petr Arenberger,Flora Balieva,M. Bylaite,Osvaldo Correia,E. Daudén,Paolo Gisondi,Lars Iversen,Lajos Kemény,M. Lahfa,Tamar Nijsten,Taina Rantanen,Adam Reich,Thomas Rosenbach,Siegfried Segaert,Catherine H. Smith,Talme T,B. Volc-Platzer,Nikhil Yawalkar +25 more